PIK3CD and leukemia: Very recently, Eldfors et al. reported promising results with idelalisib, a phosphatidylinositol 3-kinase delta (p110δ) inhibitor, in a drug-sensitivity assay with leukaemia blasts from a t(1;19)+ relapse patient [195].